Questions remain over the path forward for Samsung Bioepis once current partner Biogen sells its stake in the biosimilars joint venture to Samsung Biologics, the Korean company has acknowledged in comments to Generics Bulletin.
Certain details of Samsung Bioepis’ management, structure and strategic focus are yet to be decided, Samsung Biologics confirmed, responding to...






